Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-056017
Filing Date
2025-06-03
Accepted
2025-06-03 17:00:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 14052
  Complete submission text file 0001104659-25-056017.txt   15913
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Subject) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88114 | Film No.: 251020594
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 300 FRANK W. BURR BLVD., STE 21 TEANECK NJ 07666
Business Address 300 FRANK W. BURR BLVD., STE 21 TEANECK NJ 07666 2013297300
BFI Co., LLC (Filed by) CIK: 0001601607 (see all company filings)

EIN.: 262105186 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A